Hananeh Fonoudi

Dr. Hananeh Fonoudi serves as a Research Assistant Professor in the Department of Pharmacology at Northwestern University's Feinberg School of Medicine, where she leads research at the intersection of cardiovascular biology and stem cell technology. Her work focuses on developing human induced pluripotent stem cell (hiPSC) models to investigate cardiac development, disease mechanisms, and therapeutic interventions.

Her primary research interests encompass:

• Cardiovascular Biology
• Stem Cell Research
• Cardiotoxicity
• Cardiac Regeneration
• Molecular Cardiology
• Translational Medicine

Dr. Fonoudi's laboratory specializes in hiPSC-derived cardiomyocyte maturation, with particular emphasis on metabolic and transcriptional regulation during differentiation. She has pioneered protocols for cost-effective, weekend-free hiPSC culture and developed novel transcription factor combinations for direct cardiac reprogramming. Her recent investigations into doxorubicin-induced cardiotoxicity have identified genomic variants in drug transporters that predict individual susceptibility and potential cardioprotective strategies.

Analysis of her publication trends (2021-2024) reveals three interconnected research trajectories: (1) metabolic-transcriptional coupling in cardiomyocyte maturation, (2) pharmacogenomic approaches to cardio-oncology, and (3) optimization of stem cell differentiation systems for cardiac applications. These studies collectively advance personalized medicine in cancer therapy and regenerative cardiology.

No scientific awards or honors are documented in the available materials.

Dr. Fonoudi's research program involves collaborative grant-funded projects focused on stem cell modeling of cardiac diseases and chemotherapy-induced injury, though specific grant details and student mentorship records are not publicly specified. Her laboratory operates within Northwestern's Pharmacology department, contributing to the university's cardiovascular research initiatives through development of innovative stem cell models and cardiotoxicity screening platforms.